Koroneos, George
August 2008
Pharmaceutical Executive;Aug2008, Vol. 29 Issue 8, p42
Trade Publication
The article focuses on the efforts by pharmaceutical companies in the U.S. in implementing technologies and programs to help patients adhere to their drug regimens. Reminder messaging, nurse services and disease-state compliance programs are at the top of the companies' list of compliance efforts. It is noted that working with an outside content provider to establish a health-management program is an attractive alternative.


Related Articles

  • Health Economics & Analysis in Clinical Development. Crown, William H.; Marshall, Deborah; Barr, Charles E. // Applied Clinical Trials;Feb2007, Vol. 16 Issue 2, p44 

    The article reports on the role of health data in drug development as the U.S. pharmaceutical industry faces serious financial challenges. It has been noted that pharmaceutical companies is rethinking new drug developments and marketing strategies in response to a health care system that is...

  • Where have all the Scientists Gone?  // Pharmaceutical Executive;Mar2011, Vol. 31 Issue 3, p16 

    The article presents the view of the author on the Mechanism of Action (MOA) concept of marketing in the pharmaceutical industry in the U.S. According to the author, the MOA can be generated to support scientific approach in pharmaceutical marketing. The author also mentions that the MOA can...

  • Game Is Changing for Rx Makers.  // Chain Drug Review;8/29/2011, Vol. 33 Issue 14, p89 

    The article reports on the need for drug companies to find new ways to innovate and adapt to rapid market changes in the U.S.

  • The Future of Clinical Diagnostics. Santicerma, Anthony J.; Engelhart, Mark M.; Harvey, Michael H. // Applied Clinical Trials;Oct2004 Supplement, Vol. 13, p6 

    Focuses on the change in the drug development approaches and marketing strategy by pharmaceutical companies in the U.S. Impetus to the changes; Implications of generic drugs for the industry; Citations of the trends affecting the clinical diagnostics business.

  • ECRM Generics: REPORTERS Notebook.  // Drug Store News;2/16/2010, Vol. 32 Issue 2, p28 

    The article offers news briefs related to the pharmaceutical industry in the U.S. including the approval of the Food and Drug Administration (FDA) on Ampyra extended-release tablets from Acorda Therapeutics, the launch of Sandoz of a generic version for schizophrenia and bipolar disorder drug...

  • Productivity Perspectives. Parker, Kevin // Processing (08968659);Apr2014, Vol. 27 Issue 4, p4 

    The author comments on drug quality and serialization in the U.S. pharmaceutical industry.

  • Vantage Point. TAENZLER, JOHN // Medical Marketing & Media;Nov2012, Vol. 47 Issue 11, p30 

    The article reports on the efforts of drug manufacturers in the U.S. to develop effective marketing strategies in 2012.

  • Five tips for tightening up your tactical planning. Shields, Joe // Medical Marketing & Media;Jul2010, Vol. 45 Issue 7, p25 

    In this article the author offers tips on how marketers can improve tactical planning for their pharmaceutical companies in the U.S. He states the need to analyze plan as a brand platform and evaluate tactics that do not work and reach a broad audience. Also discussed is the need to consider...

  • Taking Advantage of the Science Behind Marketing. Chapin, David // Pharmaceutical Representative;Jan2011, Vol. 41 Issue 1, p28 

    The article focuses on marketing strategies in the pharmaceutical industry in the U.S. It notes the experiment which aims to determine the industry' immunity to marketing influences. The author also discusses the relationship between the marketer and the purchaser as well as the general...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics